Cargando…
MEDB-89. Elucidation of the Oncogenic role of Nuclear Factor I/B (NFIB) in group 3 medulloblastoma
Amongst the 4 subgroups of medulloblastoma (MB), tumors falling into group 3 are the most aggressive and associated with increased incidence of aberrations on chromosome 17p, c-Myc amplification, metastases at diagnosis, and rapid tumor relapse. Thus, patients with group 3 tumors suffer the worst pr...
Autores principales: | Perumal, Naveenkumar, Kanchan, Ranjana, Doss, David, Thapa, Ishwor, Nasser, Mohd W, Batra, Surinder, Mahapatra, Sidharth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165215/ http://dx.doi.org/10.1093/neuonc/noac079.463 |
Ejemplares similares
-
MEDB-87. Transcriptome-driven drug repurposing in group 3 medulloblastoma
por: Doss, David, et al.
Publicado: (2022) -
MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
por: Kanchan, Ranjana, et al.
Publicado: (2022) -
MBRS-72. MiR-212 FUNCTIONS AS A TUMOR SUPPRESSOR GENE IN GROUP 3 MEDULLOBLASTOMA VIA TARGETING NUCLEAR FACTOR I/B (NFIB)
por: Perumal, Naveenkumar, et al.
Publicado: (2020) -
MBRS-13. MiR-1253 POTENTIATES CISPLATIN RESPONSE IN PEDIATRIC MEDULLOBLASTOMA BY REGULATING FERROPTOSIS
por: Kanchan, Ranjana K, et al.
Publicado: (2020) -
MDB-40. TRANSCRIPTOME-BASED DRUG REPURPOSING IN GROUP 3 MEDULLOBLASTOMA
por: Doss, David, et al.
Publicado: (2023)